Dong Sung Bio Pharm.Co.,Ltd.

KRX:002210.KS

973 (KRW) • At close June 25, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

202420232022202120202019201820172016201520142013201220112010200920082007
Revenue 88,448.23488,593.58993,328.19584,407.65887,799.92786,536.75591,912.68682,385.23479,720.85574,660.37173,157.94275,175.28484,581.02178,442.09871,926.02668,724.1662,231.43460,319.47
Cost of Revenue 49,564.47747,223.99951,272.75550,864.01353,650.70453,460.24956,718.17746,281.5942,624.938,182.43237,893.89336,210.89942,056.70933,020.84631,919.44627,614.75125,271.39323,739.752
Gross Profit 38,883.75741,369.5942,055.4433,543.64534,149.22333,076.50735,194.50836,103.64437,095.95536,477.9435,264.04938,964.38642,524.31245,421.25140,006.5841,109.40936,960.04136,579.718
Gross Profit Ratio 0.440.4670.4510.3970.3890.3820.3830.4380.4650.4890.4820.5180.5030.5790.5560.5980.5940.606
Reseach & Development Expenses 4,516.9864,169.1194,115.8063,395.3283,373.3183,104.4223,004.2172,460.2632,349.4882,481.5392,478.3452,458.1532,195.74377.325193.099332.145252.34169.715
General & Administrative Expenses 1,938.4891,894.0141,833.5921,703.2271,612.6851,927.8291,780.4083,086.5543,132.3333,263.3672,809.1162,827.9122,238.1293,168.7213,222.8043,554.1984,325.9363,132.029
Selling & Marketing Expenses 25,476.46724,762.63927,003.0221,38021,838.33721,754.16119,370.14318,002.87919,469.60819,765.68919,841.78324,182.79425,459.28725,434.05925,871.81124,975.2620,639.84120,212.138
SG&A 27,414.95626,656.65328,836.61223,083.22723,451.02223,681.9921,150.55121,089.43422,601.9423,029.05722,650.89927,010.70627,697.41628,602.7829,094.61528,529.45824,965.77723,344.167
Other Expenses 13,545.1189,947.41512,200.00812,364.13810,995.65613,821.852243.471327.556796.937479.589-977.716420.2381,340.872494.887-618.704372.308202.595206.5
Operating Expenses 45,477.0640,773.18745,152.42538,842.69337,819.99640,608.26437,001.76635,148.5139,385.57335,281.04137,094.83540,931.37339,271.25442,313.58643,152.75439,979.46135,352.16534,927.954
Operating Income -6,593.303596.403-2,041.798-5,299.049-3,670.773-7,531.758-1,807.258955.133-2,289.6191,196.898-1,830.786-1,966.9883,253.0583,595.243-3,146.1771,129.9491,607.8771,651.763
Operating Income Ratio -0.0750.007-0.022-0.063-0.042-0.087-0.020.012-0.0290.016-0.025-0.0260.0380.046-0.0440.0160.0260.027
Total Other Income Expenses Net -1,062.556-1,462.289191.196919.709-7,135.113-1,233.787-4,885.822-1,521.386-253.435-452.818-1,164.472-1,147.946-494.001-1,846.647-1,905.078-453.9553,628.5661,819.781
Income Before Tax -7,655.859-865.886-1,850.602-4,379.341-10,805.885-8,765.545-6,693.079-566.253-2,543.054744.08-2,995.258-3,114.9333,591.8641,748.597-5,051.255675.9945,236.4433,471.544
Income Before Tax Ratio -0.087-0.01-0.02-0.052-0.123-0.101-0.073-0.007-0.0320.01-0.041-0.0410.0420.022-0.070.010.0840.058
Income Tax Expense -402.8531,208.024271.068-66.5083,273.253-380.341-948.522-367.989-882.61289.2427,951.692-1,126.705399.77747.5032,886.089107.5631,579.826815.591
Net Income -7,253.006-2,073.91-2,121.67-4,312.832-14,079.138-8,385.205-5,744.558-198.264-1,660.443454.838-10,946.95-1,988.2293,192.0881,701.094-7,937.344568.4313,656.6172,655.952
Net Income Ratio -0.082-0.023-0.023-0.051-0.16-0.097-0.063-0.002-0.0210.006-0.15-0.0260.0380.022-0.110.0080.0590.044
EPS -317.64-90.7-92.23-184.52-599.87-363.57-293-10-83.2923-589-11018196-44131201152.6
EPS Diluted -317.2-86.74-87.74-184.29-599.87-363.57-293-10-8323-579-10717996-44131201152.6
EBITDA -2,050.0153,421.0141,527.115-1,730.413-8,143.449-5,326.564-3,089.3772,641.608425.9023,026.13937.797163.447,465.5625,258.671-1,139.7183,693.4028,450.9453,741.219
EBITDA Ratio -0.0230.0390.016-0.021-0.093-0.062-0.0340.0320.0050.0410.0010.0020.0880.067-0.0160.0540.1360.062